Providence Health & Services — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications1liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
cetrizineThis 6-month randomized controlled pilot study will determine whether there is some evidence that cetirizine is better tolerated than diphenhydramine without an increase in Infusion-Related Reactions (IRRs) in subjects receiving ocrelizumab(OCR) for multiple sclerosis (MS).	SEP	Phase 3	À vérifier	United States	À vérifier
OCTAVE — Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to OcrelizumabThe primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI and disability progression.	SEP	À vérifier	Ralentissement de la progression	United States	À vérifier
OCTAVE — Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to OcrelizumabThe primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI and disability progression.	SEP	À vérifier	Ralentissement de la progression	United States	À vérifier
cetrizineThis 6-month randomized controlled pilot study will determine whether there is some evidence that cetirizine is better tolerated than diphenhydramine without an increase in Infusion-Related Reactions (IRRs) in subjects receiving ocrelizumab(OCR) for multiple sclerosis (MS).	SEP	Phase 3	À vérifier	United States	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
cetrizine	SEP	Phase 3	NCT04175834	PRECEPT — Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab	COMPLETED
OCTAVE — Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab	SEP	À vérifier	NCT03157830	OCTAVE — Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab	COMPLETED

Publications

1

Molécule	Indication / population	Titre	Journal	Date
OCTAVE — Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab		Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).	Multiple sclerosis (Houndmills, Basingstoke, England)